Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss
One study found that 27% of women and 19% of men on very low-calorie diets reported decreased libido, and men on an eight-week, 1,200-calorie diet experienced a 30% reduction in total testosterone levels
Lifestyle rhythms, movement, nourishment, spiritual grounding, and intentional recovery remain foundational
Start your intake How Semaglutide Produces Weight Loss Through GLP-1 Signaling Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors throughout the brain and digestive system, creating multiple pathways to weight reduction
It aids in wound healing, collagen production, and tissue repair
When in doubt, submit a sample for independent purity testing before using the material in research